Energy & Metabolic Health: weight, visceral fat, insulin resistance, and GLP‑1 therapy.
Persistent fatigue and stubborn weight gain in perimenopause and menopause are rarely about willpower. They're driven by measurable shifts in hormones, fat distribution, and insulin sensitivity — and there are effective, evidence-based ways to address the actual cause.
Common signs
Menopause changes where — and how — your body stores fat
Estrogen influences where the body stores fat and how efficiently it burns energy. As estrogen declines, fat storage tends to shift from the hips and thighs toward the abdomen — even without a change in total body weight. At the same time, resting metabolic rate and muscle mass both tend to decline, so the same diet and exercise routine that worked in your 30s often stops working in your 40s and 50s.
This isn't a motivation problem. It's a measurable hormonal and metabolic shift, and it responds best to a plan built around what's actually changing in your body — not a generic calorie-restriction plan.
Visceral fat is a metabolic risk marker, not just an appearance concern
Not all body fat behaves the same way. Visceral fat — the fat that accumulates around the abdominal organs rather than just under the skin — is metabolically active tissue that releases inflammatory signals and interferes with insulin function. It's strongly linked to cardiovascular disease, type 2 diabetes, and fatty liver disease, independent of overall body weight.
Two women with the same weight can have very different visceral fat levels and very different risk profiles. We evaluate this directly — through waist circumference, body composition, and metabolic labs — rather than relying on weight or BMI alone.
Insulin resistance often develops quietly during this transition
Insulin resistance means your cells respond less efficiently to insulin, so your body produces more of it to keep blood sugar in a normal range. Early on, standard labs can look normal even as this process is actively underway — which is why insulin resistance so often goes undetected until it has progressed toward prediabetes or type 2 diabetes.
- Declining estrogen directly reduces insulin sensitivity in muscle and fat tissue
- Increased visceral fat further worsens insulin resistance, creating a self-reinforcing cycle
- Symptoms — fatigue, sugar cravings, difficulty losing weight, brain fog after meals — often appear before labs clearly flag a problem
We screen for this proactively with fasting insulin, HOMA-IR, and A1c, rather than waiting for glucose alone to become abnormal.
GLP‑1 receptor agonists: how they work
GLP‑1 (glucagon-like peptide‑1) receptor agonists are a class of medications that mimic a hormone your gut naturally releases after eating. They're FDA-approved for type 2 diabetes and, at higher doses, for chronic weight management — and they address several of the mechanisms driving menopausal weight gain directly.
Appetite Regulation
Acts on appetite centers in the brain to reduce hunger and increase satiety, making sustainable calorie reduction significantly easier to maintain.
Slower Gastric Emptying
Food moves through the stomach more slowly, extending the feeling of fullness after meals and helping to blunt post-meal blood sugar spikes.
Improved Insulin Sensitivity
Supports more effective insulin signaling and better blood sugar regulation, addressing insulin resistance rather than just its downstream effects.
Tirzepatide: a dual-action option
Tirzepatide is a newer medication in this category that acts on two hormone pathways instead of one — both GIP and GLP‑1 receptors. That dual mechanism is associated with more substantial effects on weight and blood sugar than single-pathway GLP‑1 medications for many patients, though individual response varies. It's FDA-approved for type 2 diabetes and, under a separate brand name, for chronic weight management.
Like any prescription medication, tirzepatide isn't right for everyone — candidacy depends on your full metabolic picture, medical history, and goals, which is something we evaluate together rather than prescribing off a checklist.
Our approach to metabolic health
Full Metabolic Evaluation
Fasting insulin, HOMA-IR, A1c, lipid panel, and body composition — not just weight on a scale — to see what's actually driving your symptoms.
Hormone-Informed Treatment
We evaluate metabolic health alongside your broader hormone picture, since estrogen, thyroid, and insulin function are closely connected during this transition.
Individualized Medication Decisions
If a GLP‑1 or dual-agonist medication is appropriate for you, we discuss the specific options, expected timeline, and monitoring plan in detail before starting anything.
Ongoing Monitoring
Metabolic treatment is adjusted over time based on labs and response — not a one-time prescription with no follow-up.
"Protect your trajectory — before the choice is no longer yours."
Ready to understand what's actually driving your weight and energy?
Schedule a consultation for a full metabolic evaluation — not just a scale reading.